Clasp Therapeutics

Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations across hard-to-treat cancers. Clasp is developing T cell engagers to match both the specific characteristics of the patient’s immune system and the specific genetics of their tumor, enabling the creation of exquisitely personalized, yet off-the-shelf, therapeutics. Built upon academic research in the labs of Bert Vogelstein and Drew Pardoll at Johns Hopkins University, Clasp is backed by prominent life sciences investors including Catalio Capital Management, Third Rock Ventures and Novo Holdings. The company was launched in March 2024 and is based in Cambridge, MA and Rockville, MD. For more information about Clasp, please visit